Context: Renal cell carcinoma (RCC) accounts for 2-3% of adult malignancies. There remain uncertainties over the oncological outcomes for the surgical management of localised RCC. Objective: Systematically review relevant literature comparing oncological outcomes of surgical management of localised RCC (T1-2N0M0). Evidence acquisition: Relevant databases including Medline, Embase, and the Cochrane Library were searched up to October 2010, and an updated scoping search was performed up to January 2012. Randomised controlled trials (RCTs) or quasi-RCTs, prospective observational studies with controls, retrospective matched-pair studies, and comparative studies from well-defined registries/databases were included. The main outcomes were overall survival, cancer-specific survival, recurrence, and metastases. The Cochrane risk of bias tool was used to assess RCTs, and an extended version was used to assess nonrandomised studies (NRSs). The quality of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Evidence synthesis: A total of 4580 abstracts and 389 full-text articles were assessed. Thirty-four studies met the inclusion criteria (6 RCTs and 28 NRSs). Meta-analyses were planned but were deemed inappropriate due to data heterogeneity. There were high risks of bias and low-quality evidence across the evidence base. Open radical nephrectomy and open partial nephrectomy showed similar cancer-specific and overall survival, but when both open and laparoscopic approaches are considered together, the evidence showed improved survival for partial nephrectomy for tumours 4 cm. The overall evidence suggests either equivalent or better survival with partial nephrectomy. Laparoscopic radical nephrectomy offered equivalent survival to open radical nephrectomy, and all laparoscopic approaches achieved equivalent survival. Open and laparoscopic partial nephrectomy achieved equivalent survival. The issue of ipsilateral adrenalectomy or complete lymph node dissection with radical nephrectomy or partial nephrectomy remains unresolved. Conclusions: The evidence base suggests localised RCCs are best managed by nephronsparing surgery where technically feasible. However, the current evidence base has significant limitations due to studies of low methodological quality marked by high risks of bias.
1.

Introduction
Renal cell carcinoma (RCC) accounts for approximately 2-3% of all adult malignancies. More than 50% of all RCCs diagnosed are a localised stage (ie, T1-T2N0M0 or stage I-II) [1] . Open radical nephrectomy has been the standard curative intervention for localised RCC for the past five decades [2] . There were controversies over whether radical nephrectomy should be performed in conjunction with ipsilateral adrenalectomy, as originally described by Robson, or if the adrenal should be preserved [3] [4] [5] [6] and whether ipsilateral extended retroperitoneal lymphadenectomy or limited hilar lymphadenectomy should be performed [7, 8] .
With the advent of minimally invasive surgery, laparoscopic radical nephrectomy has become an acceptable alternative to open surgery for localised RCCs [6, 7] . Another recent controversy is the use of nephron-sparing surgery (NSS; partial nephrectomy). NSS has been the accepted mode of treatment when radical nephrectomy would render the patient anephric or at high risk for subsequent renal replacement therapy [9] . This organ-preserving approach has recently emerged as a viable alternative for small renal tumours (<4 cm or T1a) in patients with a normal contralateral kidney, with encouraging short-term and long-term oncological outcomes [10, 11] . The era of increasing use of NSSs has also witnessed the development of minimally invasive nephron-sparing interventions such as cryoablation, radiofrequency ablation (RFA), and highintensity focussed ultrasound (HIFU) for the treatment of localised renal cancer [10, 11] .
Although various guidelines exist in relation to the various interventions for localised RCC [6, 12] , it is important to recognise that such guidelines were based on reviews that were not undertaken systematically and often used methodology that was not transparent, reproducible, or robust. A systematic review of current evidence is urgently needed to establish whether the outcomes of competing treatment options are comparable. Methodological rigour is needed in assessing risks of bias and quality of evidence in a standardised and transparent way to highlight weaknesses in the evidence base and to make recommendations for future research.
The objective of this systematic review was to compare the oncological outcomes for all interventions relevant to the management of localised RCC. This paper reports the oncological outcomes, and a separate article reports the surgical and quality-of-life outcomes from this systematic review. There is also a full report published online with extra methodological information and data for oncological and surgical outcomes [13] .
2.
Evidence acquisition Auto-alerts in Medline were also run during the course of the review. Reference lists of relevant articles were also checked [13] . Two reviewers screened all abstracts and full-text articles independently. Disagreement was resolved by discussion, and where no agreement was reached, a third independent party acted as an arbiter. In addition, an updated scoping search was performed up to January 2012.
Types of study design included
All relevant randomised controlled trials (RCTs) or quasiRCTs were included. Due to the small number of RCTs, we also included nonrandomised studies (NRSs). Prospective observational studies with controls, retrospective matchedpair studies, and comparative studies from well-defined registries/databases were also included. Studies with no comparator group (eg, case series), nonmatched retrospective studies, and chart reviews were excluded.
Types of participants included
The study population was patients diagnosed with localised RCC based on computed tomography scan or magnetic resonance imaging, defined as clinical stage T1a-T2N0M0. Studies that reported pathologic T3 cases were included so long as the clinical staging was T1-2N0M0.
Types of interventions included
The following interventions were compared:
Radical nephrectomy Partial nephrectomy (NSS) Laparoscopic surgery for radical or partial nephrectomy Hand-assisted laparoscopic surgery for radical or partial nephrectomy Robot-assisted laparoscopic surgery for radical or partial nephrectomy Complete regional (extended) lymphadenectomy Partial regional (limited) lymphadenectomy Adrenalectomy RFA Cryoablation HIFU.
A valid comparator was no intervention or any of the specified interventions (see full report for definitions of interventions [13] ).
Types of outcome measures included
The principal oncological measure of effectiveness was overall survival rate at 5 and 10 yr. Other oncological measures of effectiveness were considered such as cancerspecific survival, local recurrence, metastasis, and positive surgical margins (or tumour-free rates on ablative technique). Other outcome measures including surgical outcomes (encompassing perioperative complications and long-term adverse effects), impact on quality of life, patient satisfaction, and cost effectiveness were considered and will be reported in a separate paper. For long-term outcomes, time to event data and categorical data were extracted. For categorical data, we collected event rates at 5 and 10 yr (prespecified), or if such data were not reported, we also collected data at last follow-up.
Assessment of risks of bias
The risk of bias (RoB) in the included studies was assessed using the Cochrane Risk of Bias Assessment tool for RCTs [14] . This included sequence generation; allocation concealment; blinding of participants, therapists, and outcome assessors; completeness of outcome data; selective outcome reporting; and other potential sources of bias. Two reviewers independently assessed these domains. Any differences of opinion were resolved by consensus or by consulting a third party. A modified version of the RoB assessment tool was used in assessing NRSs with the addition of further items (domains) to assess risk of bias through confounders [15] .
The five most important potential confounders (prognostic factors) for oncological outcomes identified a priori in consultation with content experts (drawn from the British Association of Urological Surgeons Section of Oncology and European Association of Urology [EAU] Renal Cell Carcinoma Guideline Panel) were tumour stage, tumour size, tumour grade (Fuhrman), necrosis, and histologic cell type.
Each of the prespecified confounders was assessed on the following four criteria:
Whether the confounder was considered by the researchers (yes or no) Precision with which confounder was measured Imbalance between groups Care with which adjustment for confounder was carried out.
Our guidelines, drawn up with clinical, statistical, and methodological advice from members of the Cochrane NonRandomised Studies Methods Group and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group, can be seen in the full report [13] .
Assessment of the quality of evidence
The GRADE evidence quality assessment tool was used to assess patient-important outcomes across studies (full report for GRADE evidence profiles [13] ). Of the seven outcomes chosen for GRADE quality assessment in consultation with clinical content experts, two were oncological outcomes and five were non-oncological outcomes. The two chosen oncological outcomes for GRADE quality assessment are reported in this review: overall survival and local recurrence or progression.
Data analysis
A quantitative synthesis (meta-analysis) was performed for trial data only. Heterogeneity of data made meta-analysis inappropriate for NRSs. In analysing dichotomous outcomes in the comparison of intervention effects, fixed-effect models were used to derive relative risk (risk ratios) with 95% confidence intervals (CIs). In analysing continuous outcomes, means and standard deviations were used to summarise the data and compare interventions with (weighted) mean difference and 95% CIs. Heterogeneity between studies was assessed by visual inspection of plots of the data, the chi-square test for heterogeneity, and the I 2 statistic [16] . Where meta-analysis was not feasible, a narrative synthesis is provided [17] . Analysis was performed using Cochrane RevMan software. Separate or subgroup analyses were planned for the following groups of patients:
Those in chronic renal failure Elderly patients (>65 yr of age) Those with a solitary kidney or a solitary functioning kidney Patients with disease predisposing them to renal tumours Different American Society of Anaesthesiology grades Different tumour stages.
However, the data were not sufficient to address any of these meaningfully.
3.
Evidence synthesis 3.1.
Risk of bias and quality assessment of the included studies
The study selection process is outlined in the Preferred Reporting Items for Systematic Reviews (PRISMA) diagram (Fig. 1 ). There were 44 studies that met inclusion criteria, and 34 of them reported oncological outcomes (6 RCTs and 28 NRSs). The Cochrane risk of bias assessment can be viewed in Appendix 1. The additional NRS risk of bias assessment adjustment scores (outlined earlier) are displayed in Table 1 , which reports baseline characteristics (all study designs) and adjustment scores (NRSs only).
Comparisons of intervention results
Principal results can be viewed in Table 2 and in the forest plots in Figures 2 and 3 . Further data can be viewed in the full report of this systematic review [13] .
Surgical (radical or partial nephrectomy) versus nonsurgical management
One database review [18] assessed this comparison. Nonsurgical management included pT1a patients who had either observation or active surveillance only. The analysis, which was based on a matched-pair population, revealed that surgical management had a 5-yr cancerspecific mortality benefit over nonsurgical (4.4% vs 12.4%) ( Table 2) . However, even though this study was matched, it is marked by indication bias. That is, the surveillance group members were indicated to that intervention and not randomly allocated to it; surveillance patients were older (mean: 73 vs 61.4 yr of age) (Table 1) , and it is likely they were generally more frail and less likely to be suitable candidates for surgery. The study was marked by other methodological flaws such as uncertain disease status in the surveillance group (indicated by failing to measure and control for two of the main prognostic confounders, ie, Fuhrman grade and histologic cell type) ( Table 1) . There were no randomised studies assessing oncological outcomes. A prospective cohort study [19] and a retrospective database review [20] , both of low methodological quality, found similar oncological outcomes with 5-yr overall survival for laparoscopic versus open radical nephrectomy reported at 87.8% versus 88.7% ( p = 0.87), respectively, in the study by Hemal et al. [19] (Table 2) ; and all-cause deaths were 3 of 36 versus 1 of 37, respectively, in the study by Gratzke and colleagues [20] (Fig. 2) . There was no evidence of any difference in cancer-specific and recurrence-free survival at 5 yr reported in the study by Hemal et al. [19] ( Table 2 ).
Retroperitoneal versus transperitoneal radical nephrectomy.
Two randomised studies [21, 22] and one quasi-randomised study [23] compared retroperitoneal and transperitoneal laparoscopic radical nephrectomy. Both approaches were found to have similar oncological outcomes. No cancerspecific deaths were reported by Nadler et al. [23] (Fig. 3) , and although Desai et al. [21] reported more all-cause deaths in the retroperitoneal approach (4 of 52 vs 2 of 50) (Fig. 2) , the result was not statistically significant. A very low number of metastatic events was reported across the studies: Nadler et al. [23] and Nambirajan et al. [22] reported none, whereas Desai et al. [21] (Fig. 3) , positive surgical margins, or recurrences (plots 3.1-3.4, full report [13] ) in the trial by Nadler and colleagues [23] (which used the transperitoneal approach only), but it should be noted that study numbers were very low with only 11 patients in each arm, and followup was short (median: 20 mo). Oncological outcomes were comparable in the study by Gabr et al. [24] (which used transperitoneal and retroperitoneal approaches). Estimated 5-yr overall survival (74% vs 79%; p = 0.69), cancer-specific survival (87.2% vs 88.9%; p = 0.76), and recurrence-free survival (81.3% vs 76.5%; p = 0.87) rates were comparable between hand-assisted and standard laparoscopic radical nephrectomy, respectively ( Table 2 ). Reported hazard ratios (HRs) favoured the hand-assisted procedure; however, the estimated CIs were wide, indicating considerable uncertainty. For example, the overall survival-adjusted HR was 0.407 (0.150-1.395) ( Only one small prospective cohort study (n = 30) compared robotic and laparoscopic radical nephrectomy [25] . There were no local recurrences, port-site, or distant metastases (plot 6.1-6.2, full report [13] ). The study groups were comparable, but sample size was small and follow-up was <1 yr.
3.2.2.6. Single-port laparoscopic radical nephrectomy versus laparoscopic radical nephrectomy. One prospective cohort study compared ''portless'' (n = 14) and three-port (n = 15) laparoscopic radical nephrectomy [26] . There were no local recurrences, but the study was small with a short follow-up (especially in the portless group; mean: 7.1 mo; range: 2.7-17.3 mo) (plot 7.1, full report [13] [29] , a prospective cohort study [20] , a database review [30] , and one retrospective matched-pair study [31] were identified that compared various aspects of the oncological effectiveness of open radical nephrectomy with open partial nephrectomy. The study populations of D'Armiento et al. [29] , Butler et al. [30] , and Lee et al. [31] included only patients with tumour sizes <4 cm. The study by Gratzke and colleagues does not give any information on tumour size, but T1-T2 patients were included. However, there were prognostically relevant baseline imbalances in the radical versus partial nephrectomy tumour stages (see Table 1 ). It is important to describe the tumour sizes in terms of whether they are >4 cm or <4 cm because historically there has been clinical uncertainty over whether partial resection is appropriate for tumours >4 cm. The RCT by D'Armiento et al. [29] reported an equal median survival time of 96 mo, although HRs for survival or survival rates were not available. Two NRSs reported the estimated overall survival rates at 5 yr. There was an inconsistency in the direction of effect: Butler et al. [30] reported 75% versus 80%, whereas Lee et al. [31] reported 98.2% versus 88.8% ( p = 0.63; Table 2 ) for open partial versus open radical nephrectomy, respectively. However, [ ( F i g . _ 2 ) T D $ F I G ] 
these estimates should be interpreted with caution because data were available for a shorter follow-up period in partial nephrectomy cases (40 AE 26 mo) than in radical nephrectomy cases (66 AE 30 mo) [30] . In addition, neither study was randomised, and prognostically important covariates such as tumour grade and cell type were not reported. The estimated cancer-specific survival rates at 5 yr for radical versus partial nephrectomy, respectively, were 97% versus 100% [30] and 97.9% versus 100% ( p = 0.98) [31] ( Table 2) . The numbers of all-cause deaths, cancer-specific deaths, local recurrences, and metastases events for open radical versus open partial nephrectomy (plots 10.1-10.4, full report [13] ) were similar but marked by low event rates and small sample sizes. Disease-free rates were similar for open versus partial nephrectomy (plot 10.5, full report [13] ).
3.2.4.1.2. Laparoscopic partial nephrectomy versus laparoscopic radical nephrectomy. One NRS, a database review [32] , compared laparoscopic partial nephrectomy (n = 35) and laparoscopic radical nephrectomy (n = 75) in tumours >4 cm. There was no evidence of a difference in estimated overall survival, cancer-specific survival, and recurrencefree survival rates, respectively, at 80 mo (Table 2 ).
Open or laparoscopic partial nephrectomy versus open or
laparoscopic radical nephrectomy. There has been controversy as to whether partial nephrectomy should be used for larger tumours, and a cut-off of 4 cm has been recommended. However, some study authors have argued that partial nephrectomy is feasible up to 7 cm with no reduction in oncological control or overall survival. For this reason this section is split into two: studies reporting populations with tumour sizes 4 cm and studies with populations reporting 4-7 cm. The surgical approach used (whether open or laparoscopic) was not clearly reported in these studies. These results should be treated with caution because there is limited high-quality evidence. [35] , and Patard et al. [36] studied small renal tumours. Huang et al. [33] and Zini et al. [34] both report data from the Surveillance Epidemiology and End Results (SEER) database. Huang et al. limited the population to those >66 yr of age; Zini et al. [34] included those aged over 18 years, and both studies adopted different analytic approaches (Huang et al. used multivariate logistic regression and Zini et al. used calliper matching).
In the study by Huang et al, about 30% of the patients died during the study period, including 110 (19.8%) in the partial nephrectomy group and 782 (32.1%) in the radical nephrectomy group. The 5-yr survival probability was 74% after partial nephrectomy and 68% after radical nephrectomy. After adjusting for patient characteristics, radical nephrectomy was found to be significantly associated with death from any cause (HR: 0.72 [0.59-0.88], p < 0.001) ( Table 2 ).
For those matched by age, tumour size, and year of surgery, Zini et al. reported an overall mortality HR of 0.84 ( p = 0.048) in favour of patients who underwent partial nephrectomy based on Cox regression modelling ( Table 2 ). The 5-yr overall survival rates of the partial nephrectomy and radical nephrectomy groups were 89.3% and 84.4%, respectively, and the 10-yr overall survival rates were 71.3% and 68.2% in favour of partial nephrectomy (Table 2) .
Thompson et al. [35] reported data from the Mayo Clinic institutional databases and found no evidence that radical and partial nephrectomy were different in terms of all-cause death (risk ratio In a subset of T1a patients (ie, 4 cm), Patard et al. [37] noted no difference in cancer-specific survival at 5 yr (logrank test p = 0.7) in a multi-institutional study. There was no evidence of differences in partial versus radical nephrectomy, respectively, in local (1 of 123 vs 1 of 175) or distant (3 of 123 vs 8 of 175) recurrence at a mean followup of 62.5 mo (plots 13.1-13.4, full report [13] [40] , Cré pel et al. [41] , and Patard et al. [36, 37] report on tumours 4-7 cm. Thompson et al. [38] , combining Mayo Clinic and Memorial SloanKettering Cancer Centre (MSKCC) institutional databases, and Weight et al. [40] , reporting SEER database data, failed to show evidence of differences between partial nephrectomy and radical nephrectomy (HR: Table 2) .
One database review [39] using MSKCC data reported an adjusted HR for disease-free survival and failed to show evidence of a difference between partial nephrectomy and radical nephrectomy (HR 0.36 [0.05-2.82]; p = 0.3) ( Table 2 ).
In the SEER database study by Weight et al. (Table 2) , at a median follow-up of 48 mo, controlling for the propensity to In a subset of T1b patients (ie, 4-7 cm), Patard et al. [37] noted no difference in cancer-specific survival at 5 yr (logrank test p = 0.8) in a multi-institutional study. There were no statistically significant differences in partial versus radical nephrectomy, respectively, in local (1 of Two database reviews [42, 43] and two matched-pair analyses [44, 45] compared laparoscopic and open techniques of partial nephrectomy. Lane and Gill [43] noted an overall survival benefit estimate in laparoscopic versus open partial nephrectomy patients when adjusting for age, gender, race, CharlsonRomano index, tumour size, hypertension, preoperative eGFR, and oncological potential (defined as predicted risk of recurrence at 5 yr) in those patients with a minimum of 1-yr follow-up (HR: 0.69 [0.45-1.02]; p = 0.07). At 7-yr followup, there was no evidence of a difference between the two groups. There were no differences in 3-yr cancer-specific survival [42] and 5-yr overall survival [45] (Table 2) .
Regarding the number of deaths during the study period, a lower risk of all-cause death was shown in the laparoscopic group (RR: 0.4 [0.28-0.59]; p = 0.0001) [43] (Fig. 2) .
The studies by Gill et al. [42] and Marszalek et al. [45] reported no statistically significant difference in the recurrence patterns between laparoscopic and open partial nephrectomy (Table 2) .
It is important to note that the evidence base for this comparison remains poor, with all studies suffering from methodological flaws inherent in most NRSs.
Robotic partial nephrectomy versus laparoscopic partial nephrectomy
There were no comparative studies that reported on oncological outcomes. A database review by Wu et al. [46] compared patients who underwent standard laparoscopic partial nephrectomy (n = 36, but only 24 were RCCs) and radiofrequency-assisted robotic laparoscopic partial nephrectomy (RFRCPN) (n = 42, but only 32). The groups were comparable for positive surgical margins (0 of 42 vs 1 of 36) and recurrence rates (1 of 34 vs 0 of 34) (plots 16.1-16.2, full report [13] ) for the RFRCPN and RFA-assisted robotic laparoscopic nephrectomy, but the study was marked by very low event rates, a high number of benign tumours, and lacked longer term survival data. [47] and one matched-pair study [48] . For the cryoablation and partial nephrectomy arms, respectively, 3 of 78 and 0 of 153 deaths were reported by Desai et al. [47] at last follow-up (Fig. 3) . Time to detection of local recurrence was noted at a mean follow-up time of 5.8 mo among those who underwent partial nephrectomy (1 of 153), and 24.6 mo after cryoablation (2 of 78) [47] (plot 17.1, full report [13] ). No recurrences were reported in either treatment group after a mean follow-up of 9.8 and 11.9 mo in the report by O'Malley et al. [48] (plot 17.2, full report [13] ). oncological outcomes in terms of development of recurrence therefore differed between the two studies. This may be a reflection of different definitions and ways of establishing disease recurrence following cryoablation. The study also includes data on benign tumours and therefore should be treated with caution. Determining local recurrence on imaging alone is known to be subjective. Data were obtained from one matched comparison [49] . There were no local recurrences or metastases in either group (plots 18.1-18.2, full report [13] ). However, there were only 20 patients in each arm, and follow-up was short at 27-28 mo.
Discussion
Principal findings
Open radical nephrectomy and open partial nephrectomy show no difference in either overall or cancer-specific survival. However, if data from studies comparing open or laparoscopic radical nephrectomy versus open or laparoscopic partial nephrectomy are considered, the evidence base indicates improved survival for partial nephrectomy in tumours 4 cm. However, there is no evidence of a difference in tumours >4 cm. Recurrence rates and metastases appear similar for all approaches. Although the included studies differed in quality and outcomes reported, overall the evidence suggests either equivalent or better survival with partial nephrectomy, suggesting that NSS should be applied when possible.
Laparoscopic radical nephrectomy appears to offer equivalent survival to open radical nephrectomy, and all laparoscopic approaches achieve equivalent survival. Open and laparoscopic partial nephrectomy achieve equivalent survival. Different laparoscopic and ablative techniques also achieve similar survival, but studies are of low methodological quality.
There is no evidence to support removal of the ipsilateral adrenal gland with radical nephrectomy. The performance of complete lymph node dissection with radical nephrectomy for localised RCC remains unanswered due to large inconsistencies in the data.
Although this systematic review compared surgical management with nonsurgical management for renal tumours, the evidence available falls short of proving that surgery improves survival, due to the absence of highquality studies. However, from a practical point of view, this is a question that could be answered for surveillance of small renal masses but it is unlikely to be answered for larger or more advanced tumours due to the ethical implications of withholding treatment.
Since the last search update for this review (October 2010), several potentially relevant studies have been published. An updated scoping exercise performed in January 2012 returned 240 abstracts, from which 4 relevant studies were identified, of which 2 are RCTs [50, 51] and 2 are nonrandomised retrospective matched-pair analyses [52, 53] . The study by van Poppel et al. [50] was a multicentre RCT of NSS versus radical nephrectomy for T1-T2 renal cancers. Despite being an RCT, the study had significant limitations (including premature closing of the study due to poor accrual, a change in protocol, and being significantly underpowered), a fact the authors acknowledged. The results from the intention-to-treat analysis showed a lower overall survival for NSS compared with radical nephrectomy, although this difference becomes insignificant if the analysis is restricted to the targeted population of RCC patients and those who are clinically and pathologically eligible. Given such methodological flaws and uncertainty, the results from this study should be interpreted cautiously. Yu et al. [51] The results showed similar recurrence rate and cancer-specific mortality for both procedures.
Strengths and limitations
The strength of this review is the systematic approach taken to examine the evidence base using a methodologically rigorous review process including Cochrane methodology throughout, reporting standards such as PRISMA, using novel tools to assess risks of bias in NRSs, and requesting peer review throughout from a reference group of international experts. A clinical care pathway identifying the major comparisons of interest was formulated in consultation with international experts. An in-depth description of this consensus-building process was previously reported [54] .
The major limitation of this systematic review results from the methodological concessions that needed to be made to ensure the review reflects the current state of the available evidence base. In particular, the inclusion criteria had to be more inclusive of study designs from further down the hierarchy of evidence than is desirable (full report [13] ). Another limitation is that NRSs have inherent biases, meaning they should always be treated with caution. The review has addressed this by using a methodologically rigorous system of assessing risks of bias in NRS (see full report [13] ). In addition, it was not possible to perform meta-analyses for all outcomes of interest, due to statistical and trial design limitations. However, to derive the highest possible level of evidence for the review, uncontrolled case series (ie, nonrandomised studies without a control arm) were excluded because such studies can provide level 4 evidence only at best [55] for comparative assessments of interventions.
3.4.3. How this systematic review compares with other recent systematic reviews and technology assessments by guideline panels
The current EAU and American Urological Association (AUA) Renal Cancer Guidelines provide primary reference points for the management of localised RCC. The review methodology underpinning both guidelines differ from that offered in this systematic review mainly on the point of strict inclusion criteria for primary reports and the assessment of the methodological quality of those included reports (full report [13] ).
There are specific methodological limitations of the research underpinning the AUA Renal Cancer Guidelines, such as conduct of meta-analyses of observational studies. The guideline itself acknowledged that it may not be methodologically appropriate to do so [56, 57] . The current internationally recognised EAU Renal Cancer Guidelines include many case series (ie, no comparator groups) that are susceptible to selection biases. In coauthoring this systematic review, EAU Renal Cancer Guideline Panel members and the UCAN Systematic Review Team used the most rigorous research methods to assess the best evidence available for the management of localised RCC. A comparison between this systematic review with two other reviews [58, 59] can be accessed in the full report [13] . Other reviews were either not systematically performed [60] or were based on noncomparative case series [61, 62] ; these are not considered any further.
Conclusions
Patient and tumour characteristics permitting, the current oncological outcomes evidence base suggests that localised RCCs are best managed by NSS rather than by radical nephrectomy irrespective of surgical approach. Where open surgery is deemed necessary, open NSS oncological outcomes are at least as good as open radical nephrectomy and should be the preferred option when technically feasible. The evidence around minimally invasive ablative technologies is weak due to low methodological quality studies and mixed patient populations that include benign renal lesions, making judgements about effectiveness unsafe. In the absence of obvious tumour involvement of the ipsilateral adrenal gland, the evidence available does not support routine removal of the adrenal gland. It remains unclear whether complete lymph node dissection has any role in the management of localised RCC due to large inconsistencies in limited data, and therefore on currently available evidence it is best not to offer it to patients. Future research efforts must aim to rectify this paucity of evidence with well-designed and well-reported prospective studies, especially for newer interventions. Studies should use predefined, ideally standardised, measures of outcome and be multicentre to ensure that the studies give sufficiently precise estimates of the various outcomes. Ideally, allocation should be randomised. There is an urgent need for standardisation of outcome reporting in RCC trials, observational studies, and registry databases. Such standardisation will make it easier to compare, contrast, and synthesise the results of such studies, reduce the risk of inappropriate outcomes being measured, and reduce outcome reporting bias.
Author contributions: James N'Dow had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
